Methamphetamine Enhances the Development of Schizophrenia in First-Degree Relatives of Patients with Schizophrenia

Li, Huabing; Lu, Qiong; Xiao, Enhua; Li, Qiuyun; He, Zhihui; Mei, Xilong

doi:10.1177/070674371405900206

Cited by 28 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meth is amongst the most used illicit substance in people with schizophrenia (11). Importantly, chronic meth use might promote the development of schizophrenia in at-risk individuals (12,13), and a major animal model to capture some of schizophrenia-like psychotic symptoms relies on chronic meth exposure (14). For example, impairment in prepulse inhibition, a measurement of sensorimotor gating deficits often observed in people with schizophrenia (15), can be elicited following chronic meth exposure in rodents (16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

et al. 2019

View full text Add to dashboard Cite

Despite the prevalence of methamphetamine (meth) use disorder, research on meth is disproportionately scarce compared to research on other illicit drugs. Existing evidence highlights cognitive deficits as an impediment against daily function and treatment of chronic meth use. Similar deficits are also observed in schizophrenia, and this review therefore draws on schizophrenia research by examining similarities and differences between the two disorders on cognition and related neural findings. While meth use disorder and schizophrenia are two distinct disorders, they are highly co-morbid and share impairments in similar cognitive domains and altered brain structure/function. This narrative review specifically identifies overlapping features such as deficits in learning and memory, social cognition, working memory and inhibitory/impulse control. We report that while working memory deficits are a core feature of schizophrenia, such deficits are inconsistently observed following chronic meth use. Similar structural and functional abnormalities are also observed in cortical and limbic regions between the two disorders, except for cingulate activity where differences are observed. There is growing evidence that targeting cognitive symptoms may improve functional outcome in schizophrenia, with evidence of normalized abnormal brain activity in regions associated with cognition. Considering the overlap between meth use disorder and schizophrenia, targeting cognitive symptoms in people with meth use disorder may also improve treatment outcome and daily function.

show abstract

Section: Introductionmentioning

confidence: 99%

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

et al. 2019

View full text Add to dashboard Cite

show abstract

“…18,46 It has also been shown that methamphetamine abuse in individuals at familial risk causes schizophrenia that persists regardless of whether the drug abuse continues. 16 An extrapolation of these findings 7 The adjusted model includes age, gender, and family history as covariates in addition to controlling for clustering of individuals within families.…”

Section: Discussionmentioning

confidence: 99%

“…Data from adults indicate that genetic liability to stimulant-induced psychosis overlaps with genetic liability for schizophrenia 15 and that stimulants may cause schizophrenia in individuals at familial risk. 16 These findings suggest that the risk of psychotic adverse effects of stimulants may be higher in youth with a family history of mental illness. This contingency could be clinically important because ADHD is more common among offspring of parents with severe mental illness 17 and because psychotic symptoms induced by stimulants may signal long-lasting vulnerability to psychosis.…”

mentioning

confidence: 98%

“…This contingency could be clinically important because ADHD is more common among offspring of parents with severe mental illness 17 and because psychotic symptoms induced by stimulants may signal long-lasting vulnerability to psychosis. 16,18 To our knowledge, psychotic adverse effects of stimulant medication have not been studied in youth at familial risk for mental illness. Therefore, we systematically examined the association between stimulant use and psychotic symptoms in a sample of youth at familial risk of severe mental illness.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness

et al. 2016

View full text Add to dashboard Cite

BACKGROUND: Stimulants, such as methylphenidate, are among the most commonly used medications in children and adolescents. Psychotic symptoms have been reported as rare adverse reactions to stimulants but have not been systematically inquired about in most previous studies. Family history of mental illness may increase the vulnerability to druginduced psychotic symptoms. We examined the association between stimulant use and psychotic symptoms in sons and daughters of parents with major mood and psychotic disorders.

show abstract

“…Alcohol and drug use, particularly cannabis and amphetamine, might initiate psychosis in people susceptible to schizophrenia (Pogue-Geile & Harrow, 1984;Li, Lu, Xiao, Li, He, & Mei, 2014;Medhus, Rognli, Gossop, Holm, Mørland, & Bramness, 2015). Substance abuse is strongly linked to the recurrence of schizophrenia symptoms (Moore, Mancuso, & Slade, 2012).…”

Section: Possible Causes Of Schizophreniamentioning

confidence: 99%

A Survey Towards Holistic Management of Schizophrenia

Ganguly¹,

Moustafa²

2018

JPR

View full text Add to dashboard Cite

Holistic management of schizophrenia involves main stream pharmacological intervention, complimentary medicine intervention, therapeutic intervention, and other psychosocial factors, such as accommodation, education, job training, employment, relationship, friendship, exercise, overall well-being, smoking, substance abuse, suicide prevention, stigmatisation, recreation, entertainment, violent behaviour, arrangement of public trusteeship and guardianship, day-day-living skill, integration with community, management of overweight due to medications, and other health complications related to medications amongst others. Our review shows that there is no integrated survey by combining all these factors. We are conducting an international web based survey to evaluate the significance of all these factors and present them in a unified manner. We believe this investigation will contribute positively towards holistic management of schizophrenia. There will be two surveys. In the pharmacological intervention survey, five popular drugs for schizophrenia will be chosen and their efficacy as well as harmful side effects will be evaluated in a scale of 0-10. This survey will be done by psychiatrists. In the second survey, each element of therapeutic intervention and psychosocial factors will be evaluated according to their significance in a scale of 0-10. This survey will be done by care givers, psychologists, case managers, and case workers. For the first survey, we will contact the professional bodies of the psychiatrists in English speaking countries and request them to ask their members to participate in the survey. For the second survey, we will contact the professional bodies of clinical psychologist and care givers in English speaking countries and request them to ask their members to participate in the survey. Additionally for both the surveys, we will contact the relevant professionals through personal contact networks. For both the surveys, mean, mode, median, standard deviation, and net promoter score will be calculated for each factor and presented then in a statistically significant manner. Subsequently, each factor will be ranked according to their statistical significance. Additionally, country specific variation will be highlighted to identify the variation pattern. The results of these surveys will identify the relative significance of each type of pharmacological intervention, each type of therapeutic intervention, and each type of psychosocial factor. The determination of this relative importance will definitely contribute to the improvement in quality of life for individuals with schizophrenia.

show abstract

Methamphetamine Enhances the Development of Schizophrenia in First-Degree Relatives of Patients with Schizophrenia

Abstract: Our study provides direct evidence for the causative role of MA use in the etiology of schizophrenia and highlights the role of MA-induced brain abnormalities in cognitive deficiency and development of schizophrenia.

Cited by 28 publications

References 29 publications

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

Cognition and Related Neural Findings on Methamphetamine Use Disorder: Insights and Treatment Implications From Schizophrenia Research

Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness

A Survey Towards Holistic Management of Schizophrenia

Contact Info

Product

Resources

About